Minkyong Yoo

Minkyong Yoo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YLYoung Ki Lee
Young Ki Lee
ELEun Kyung Lee
Eun Kyung Lee
YLYou Jin Lee
You Jin Lee
BEBang Wool Eom
Bang Wool Eom
HYHong Man Yoon
Hong Man Yoon
KRKeun Won Ryu
Keun Won Ryu
We evaluated the metabolic effects of gastrectomies and endoscopic submucosal dissections (ESDs) in early gastric cancer (EGC) patients with type 2 diabetes mellitus (T2DM). Forty-one EGC patients with T2DM undergoing gastrectomy or ESD were prospectively evaluated. Metabolic parameters in the patients who underwent gastrectomy with and without a duodenal bypass (groups 1 and 2, n = 24 and n = 5, respectively) were compared with those in patients who underwent ESD (control, n = 12). After 1 year, the proportions of improved/equivocal/worsened glycemic control were 62.5%/29.2%/8.3% in group 1, 40.0%/60.0%/0.0% in group 2, and 16.7%/50.0%/33.3% in the controls, respectively (p = 0.046). The multivariable ordered logistic regression analysis results showed that both groups had better 1-year glycemic control. Groups 1 and 2 showed a significant reduction in postprandial glucose (−97.9 and −67.8 mg/dL), body mass index (−2.1 and −2.3 kg/m2), and glycosylated hemoglobin (group 1 only, −0.5% point) (all p < 0.05). Furthermore, improvements in group 1 were more prominent when preoperative leptin levels were high (p for interaction < 0.05). Metabolic improvements in both groups were also observed for insulin resistance, leptin, plasminogen activator inhibitor-1, and resistin. Gastrectomy improved glycemic control and various metabolic parameters in EGC patients with T2DM. Patients with high leptin levels may experience greater metabolic benefits from gastrectomy with duodenal bypass.

25 August 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
SKSo Young Kim
So Young Kim
GWGyung-Ah Wie
Gyung-Ah Wie
YCYeong-Ah Cho
Yeong-Ah Cho
HKHyun-Hee Kang
Hyun-Hee Kang
KRKyoung-A. Ryu
Kyoung-A. Ryu
HJHyojee Joung
Hyojee Joung
Markedly increased red meat consumption is a cancer risk factor, while dietary flavonoids may help prevent the disease. The purpose of this study was to investigate the associations of red meat and flavonoid consumption with cancer risk, based on data from 8024 subjects, drawn from the 2004–2008 Cancer Screening Examination Cohort of the Korean National Cancer Center. Hazard ratios (HRs) were obtained by using a Cox proportional hazard model. During the mean follow-up period of 10.1 years, 443 cases were newly diagnosed with cancer. After adjusting for age, there was a significant correlation between cancer risk and the daily intake of ≥43 g of red meat per day (HR 1.31; 95% CI 1.01, 1.71; p = 0.045), and total flavonoid intake tended to decrease cancer risk (HR 0.70; 95% CI 0.49, 0.99; highest vs. lowest quartile; p-trend = 0.073) in men. Following multivariable adjustment, there were no statistically significant associations between flavonoid intake and overall cancer risk in individuals with high levels of red meat intake. Men with low daily red meat intake exhibited an inverse association between flavonoid consumption and cancer incidence (HR 0.41; 95% CI 0.21, 0.80; highest vs. lowest; p-trend = 0.017). Additional research is necessary to clarify the effects of flavonoid consumption on specific cancer incidence, relative to daily red meat intake.

27 October 2017 in Nutrients
Verified
Journal Article
Open access
PDF file
SKSo Young Kim
So Young Kim
GWGyung-Ah Wie
Gyung-Ah Wie
YCYeong-Ah Cho
Yeong-Ah Cho
HKHyun-Hee Kang
Hyun-Hee Kang
KRKyoung-A. Ryu
Kyoung-A. Ryu
HJHyojee Joung
Hyojee Joung
The authors have requested the following corrections to their paper